24.01.2014 Views

CDC Article-US Medical Eligibility Criteria for Contraceptive Use, 2010

CDC Article-US Medical Eligibility Criteria for Contraceptive Use, 2010

CDC Article-US Medical Eligibility Criteria for Contraceptive Use, 2010

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

66 MMWR June 18, <strong>2010</strong><br />

TABLE. (Continued) Classifications <strong>for</strong> barrier methods,* † including condoms, spermicides, and diaphragms/caps<br />

Category<br />

Condition<br />

b. Malabsorptive procedures: decrease absorption<br />

of nutrients and calories by shortening the<br />

functional length of the small intestine (Rouxen-Y<br />

gastric bypass, biliopancreatic diversion)<br />

Cardiovascular Disease<br />

Multiple risk factors <strong>for</strong> arterial cardiovascular<br />

disease (such as older age, smoking, diabetes,<br />

and hypertension)<br />

Condom<br />

Spermicide<br />

Diaphragm/<br />

cap<br />

1 1 1<br />

1 1 1<br />

Clarifications/Evidence/Comments<br />

Hypertension<br />

a. Adequately controlled hypertension 1 1 1<br />

b. Elevated blood pressure levels (properly taken<br />

measurements)<br />

i. Systolic 140–159 mm Hg or<br />

1 1 1<br />

diastolic 90–99 mm Hg<br />

ii. Systolic ≥160 mm Hg or diastolic ≥100 mm 1 1 1<br />

Hg §<br />

c. Vascular disease 1 1 1<br />

History of high blood pressure during<br />

pregnancy (where current blood pressure is<br />

measurable and normal)<br />

1 1 1<br />

Deep venous thrombosis (DVT)/pulmonary<br />

embolism (PE)<br />

a. History of DVT/PE, not on anticoagulant<br />

therapy<br />

i. Higher risk <strong>for</strong> recurrent DVT/PE (≥1 risk 1 1 1<br />

factors)<br />

• History of estrogen-associated DVT/PE<br />

• Pregnancy-associated DVT/PE<br />

• Idiopathic DVT/PE<br />

• Known thrombophilia, including antiphospholipid<br />

syndrome<br />

• Active cancer (metastatic, on therapy,<br />

or within 6 mos after clinical remission),<br />

excluding non-melanoma skin cancer<br />

• History of recurrent DVT/PE<br />

ii. Lower risk <strong>for</strong> recurrent DVT/PE (no risk 1 1 1<br />

factors)<br />

b. Acute DVT/PE 1 1 1<br />

c. DVT/PE and established on anticoagulant<br />

therapy <strong>for</strong> at least 3 mos<br />

i. Higher risk <strong>for</strong> recurrent DVT/PE (≥1 risk 1 1 1<br />

factors)<br />

• Known thrombophilia, including antiphospholipid<br />

syndrome<br />

• Active cancer (metastatic, on therapy,<br />

or within 6 mos after clinical remission),<br />

excluding non-melanoma skin cancer<br />

• History of recurrent DVT/PE<br />

ii. Lower risk <strong>for</strong> recurrent DVT/PE (no risk 1 1 1<br />

factors)<br />

d. Family history (first-degree relatives) 1 1 1<br />

e. Major surgery<br />

i. With prolonged immobilization 1 1 1<br />

ii. Without prolonged immobilization 1 1 1<br />

f. Minor surgery without immobilization 1 1 1<br />

Known thrombogenic mutations § (e.g., factor V<br />

Leiden; prothrombin mutation; protein S, protein C,<br />

and antithrombin deficiencies)<br />

1 1 1 Clarification: Routine screening is not appropriate because of the rarity of the<br />

conditions and the high cost of screening.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!